Focus: EBR Systems is a publicly traded medical-device company focused on wireless cardiac stimulation, specifically developing the WiSE system for cardiac resynchronization therapy in heart failure patients. The company is based in Sunnyvale, CA and operates as a specialized cardiovascular-focused biotech.
Profile data last refreshed 4h ago · AI intelligence enriched Yesterday
EBR Systems offers early-stage cardiovascular impact potential but carries severe near-term financial risk; suitable only for risk-tolerant candidates in growth roles willing to accept high failure probability.
Help build intelligence for EBR Systems
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from EBR Systems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
EBR Systems Sinks 8.6% as Investors Take Profits from the Medical-Technology Stock - Kalkine
EBR Systems Sinks 8.6% as Investors Take Profits from the Medical-Technology Stock Kalkine
ASX Quarterly Healthcare Wrap - Herald Sun
ASX Quarterly Healthcare Wrap Herald Sun
ASX Quarterly Healthcare Wrap - Adelaide Now
ASX Quarterly Healthcare Wrap Adelaide Now
Telix Pharmaceuticals (ASX:TLX) Slips: What Are Investors Watching Beyond the Daily Move? - Kalkine
Telix Pharmaceuticals (ASX:TLX) Slips: What Are Investors Watching Beyond the Daily Move? Kalkine
EBR Systems (ASX:EBR) Advances WiSE Commercial Rollout as Implant Activity and U.S. Market Expansion Progress - Kalkine
EBR Systems (ASX:EBR) Advances WiSE Commercial Rollout as Implant Activity and U.S. Market Expansion Progress Kalkine
Health Check: Like our sports stars, biotechs show no quarter in quest for glory - Stockhead
Health Check: Like our sports stars, biotechs show no quarter in quest for glory Stockhead
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 6 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo